Evidence map›Paper›PMID 32391656›Full record

Trial reportBJS open2020

Long-term outcomes after perioperative treatment with omega-3 fatty acid supplements in colorectal cancer.

L Schmidt Sørensen, S Ladefoged Rasmussen, P C Calder, M Nytoft Yilmaz, E Berg Schmidt, O Thorlacius-Ussing

Open access · goldAbstract readClinical Trial, Phase IVRandomized Controlled Trial
In one paragraph

Trial report in BJS open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

L Schmidt SørensenDepartment of Gastrointestinal Surgery, Aalborg, Denmark.
S Ladefoged RasmussenDepartment of Gastrointestinal Surgery, Aalborg, Denmark.ORCID 0000-0002-2560-4877
P C CalderHuman Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK.
M Nytoft YilmazDepartment of Oncology, Aalborg, Denmark.
E Berg SchmidtDepartment of Cardiology, Aalborg, Denmark.
O Thorlacius-UssingDepartment of Gastrointestinal Surgery, Aalborg, Denmark.
Aalborg University Hospital · DKAalborg University · DKUniversity Hospital Southampton NHS Foundation Trust · GB

Funding

Aase and Ejnar Danielsens FoundationAugustinus FondenL. F. Foghts FoundationThe Obel Family Foundation
6 · The paper itself

Abstract

backgroundThis study aimed to evaluate the effect of perioperative supplementation with omega-3 fatty acids (n-3 FA) on perioperative outcomes and survival in patients undergoing colorectal cancer surgery.

methodsPatients scheduled for elective resection of colorectal cancer between 2007 and 2010 were randomized to either an n-3 FA-enriched oral nutrition supplement (ONS) twice daily or a standard ONS (control) for 7 days before and after surgery. Outcome measures, including postoperative complications, 3-year cumulative incidence of local or metastatic colorectal cancer recurrence and 5-year overall survival, were compared between the groups.

resultsOf 148 patients enrolled in the study, 125 (65 patients receiving n-3 FA-enriched ONS and 60 receiving standard ONS) were analysed. There were no differences in postoperative complications after surgery (P = 0·544). The risk of disease recurrence at 3 years was similar (relative risk 1·66, 95 per cent c.i. 0·65 to 4·26).The 5-year survival rate of patients treated with n-3 FA was 69·2 (95 per cent c.i. 56·5 to 78·9) per cent, compared with 81·7 (69·3 to 89·4) per cent in the control group (P = 0·193). After adjustment for age, stage of disease and adjuvant chemotherapy, n-3 FA was associated with higher mortality compared with controls (hazard ratio 1·73, 95 per cent c.i. 1·06 to 2·83; P = 0·029). The interaction between n-3 FA and adjuvant chemotherapy was not statistically significant.

conclusionPerioperative supplementation with n-3 FA did not confer a survival benefit in patients undergoing colorectal cancer surgery. n-3 FA did not benefit the subgroup of patients treated with adjuvant chemotherapy or decrease the risk of disease recurrence.

Indexed as

Dietary SupplementsAgedAged, 80 and overChemotherapy, AdjuvantColorectal NeoplasmsCombined Modality TherapyDenmarkDouble-Blind MethodElective Surgical ProceduresFatty Acids, Omega-3FemaleHumansMaleMiddle AgedPerioperative CarePostoperative ComplicationsFatty Acids, Omega-3

Identifiers

PMID32391656
PMCPMC7397352
OpenAlexW3021076331

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.